UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CURIUM US LLC,
Petitioner,

v.

UNIVERSITÄT HEIDELBERG AND THE EUROPEAN ATOMIC ENERGY COMMUNITY (EURATOM), REPRESENTED BY THE EUROPEAN COMMISSION,
Patent Owners.

Case No. IPR2025-01582
U.S. Patent No. 10,980,901 B2

PATENT OWNERS' CORRECTED EXHIBIT LIST

CORRECTED EXHIBIT LIST

Exhibit No.	Description
2070	Center MM, et al., International variation in prostate cancer incidence and mortality rates. *Eur Urol*. 2012;61(6):1079–92
2071	Bidkar, AP, et al., Actinium-225 targeted alpha particle therapy for prostate cancer, Theranostics 2024 14(7):2969-2992.
2072	Miederer, M, et al., Pharmacokinetics, Dosimetry, and Toxicity of the Targetable Atomic Generator, 225Ac-HuM195, in Nonhuman Primates, *J Nucl. Med.* 2004; 45:129–137
2073	Declaration by Dr. Morgenstern
2074	The Journal of Nuclear Medicine, About the Cover, December 1, 2016, Vol. 57, Issue 12, https://jnm.snmjournals.org/content/57/12.cover-expansion (last visited November 21, 2023)
2075	U.S. Patent No. 10,471,160 (the "'160 Patent")
2076	Declaration by Dr. Kratochwil
2077	Declaration by Dr. Kopka
2078	Benešová, M, *et al.*, Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer, *J Nucl Med*. 2015; 56:914–920
2079	U.S. Patent No. 10,398,791
2080	Transcript of Deposition of Rebecca Abergel, Ph.D., Fusion Pharmaceuticals, Inc. -v- Universität Heidelberg, et al. (PTAB), November 16, 2023 ("Abergel Tr.")
2081	NCT04597411: Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer https://www.clinicaltrials.gov/study/NCT04597411 (last visited 11/16/2025)

Exhibit No.	Description
2082	NCT07054346: Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 (LUTACT) https://www.clinicaltrials.gov/study/NCT07054346?term=NCT07054346&rank=1 (last visited 11/16/2025)
2083	NCT07150715: Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma (ANDROMEDA) https://www.clinicaltrials.gov/study/NCT07150715?term=NCT07150715&rank=1 (last visited 11/16/2025)
2084	NCT06855277: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (AcTFirst) https://www.clinicaltrials.gov/study/NCT06855277?term=NCT06855277&rank=1 (last visited 11/16/2025)
2085	NCT06780670: Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy (PSMAcTION) https://www.clinicaltrials.gov/study/NCT06780670?term=NCT06780670&rank=1 (last visited 11/16/2025)
2086	NCT06909825: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) https://www.clinicaltrials.gov/study/NCT06909825?term=NCT06909825&rank=1 (last visited 11/16/2025)

Exhibit No.	Description
2087	NCT06402331: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (AlphaBreak) https://www.clinicaltrials.gov/study/NCT06402331?term=NCT06402331&rank=1 (last visited 11/16/2025)
2088	NCT05219500: Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resistant Prostate Cancer (TATCIST). (TATCIST) https://www.clinicaltrials.gov/study/NCT05219500?term=NCT05219500&rank=1 (last visited 11/16/2025)
2089	NCT05902247: Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy (225AcPSMAI&T) https://www.clinicaltrials.gov/study/NCT05902247?term=NCT05902247&rank=1 (last visited 11/18/2025)
2090	Max Beauroyre, *Clinical-Trial Costing 101: Building a Phase-By-Phase Budget Your Board Will Trust*, Abacum (June 25, 2025), https://www.abacum.ai/blog/clinical-trial-costing (last visited 11/16/2025)

Exhibit No.	Description
2091	Certified Clinical Rsch. Pros. Soc'y (CCRPS), *Phase III Clinical Trials: Definitive Guide & Case Studies* (June 8, 2025), https://ccrps.org/clinical-research-blog/phase-iii-clinicaltrials-definitive-guide-amp-case-studies#:~:text=Why%20are%20Phase%20III%20trials,costly%20phase%20in%20drug%20development (last visited 11/16/2025)
2092	Sertkaya, A. *et. al*., Costs of Drug Development and Research and Development Intensity in the US, 2000-2018. *JAMA Network* 2024;7(6):e2415445
2093	Calais, J. et al., Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer, *Cancer Treat. Rev* 2023;115:102524
2094	Google data for Kratochwil, et al, 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer, https://scholar.google.com/scholar?hl=en&as_sdt=0%2C34&q=225+Ac-PSMA-617+for+PSMA-Targeted+%CE%B1-+Radiation+Therapy+of+Metastatic+Castration-Resistant+Prostate+Cancer&btnG= (last visited 10/21/2025)
2095	Altmetric data for Kratochwil, et al, 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer, https://www.altmetric.com/details/9534712#score (last visited 10/21/2025)
2096	U.S. Patent Application Publication No. 2025/0303004 A1

Exhibit No.	Description
2097	Kratochwil, C, *et al.*, Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with ^{225}Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control, *J Nucl Med.* 2018 May;59(5):795-802.
2098	Sathekge, M, *et al.*, Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving ^{225}Ac-PSMA-617 Radioligand Therapy*, J Nucl Med.* 2020 Jan;61(1):62-69.
2099	Rathke, H, *et al.*, First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT, *European Journal of Nuclear Medicine and Molecular Imaging* (2021) 48:311–312.
2100	Kratochwil, C, *et al.*, Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes, *J Nucl Med*. 2020; 61:683–688
2101	Kratochwil, C, *et al.*, Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with ^{225}Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding, *J Nucl Med.* 2017 Oct;58(10):1624-1631. ("Kratochwil 2017")
2102	van der Doelen, MJ, *et al.*, Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy, *Urologic Oncology* (2021) 39:729.e7−729.e16
2103	Curium BidCo S.a.r.l. Consolidated Financial Statements and Consolidated Management Report for the Year Ended December 31, 2023
2104	Curium Locations https://www.dnb.com/business-directory/company-profiles.curium_us_holdings_llc.6eed735ca84fb91650ac6a1d54ecee08.html (last visited 11/12/2025)

Exhibit No.	Description
2105	Curium US Holdings LLC Notice of Reorganization Closing and Name Change Notification for Curium US PET LLC
2106	Curium US Holdings LLC Application for Approval of Transfer of Control
2107	Curium: What we do https://www.curiumpharma.com/about/what-we-do/#:~:text=We%20specialize%20in%20the%20production,treatment%20and%20proven%20patient%20outcomes. (last visited 11/12/2025)
2108	Feng, Y., et. al. A Third Generation PSMA-targeted Agent [211At]YF2: Synthesis and In Vivo Evaluation, *Nucl. Med. Biol.* 2024:134-135 ("Feng")
2109	Curriculum Vitae of Dr. Thomas A. Hope, M.D. prepared 11/11/2023
2110	Cimons et al., "Cancer Drugs Face Long Road From Mice to Men," Los Angeles Times, https://www.latimes.com/archives/la-xpm-1998-may-06-mn-46795-story.html (1998).
2111	Denison,TA et al, Tumor Heterogeneity and its Implication to Drug Delivery, *J Control Release* 2012 December 10; 164(2): 187-191.doi:10.10116/j.jconrel.2012.04.014. ("Denison")
2112	Turner, PG, et al. ^{223}Ra and other bone-targeting radiopharmaceuticals—the translation of radiation biology into clinical practice. Fr. J. Radiol 2015:88:20140752 at 5. ("Turner")
2113	Abou, DS, *et al*., Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis, *J Natl Cancer Inst* 2016; 108(5): djv380
2114	DeBlonde, GJ, Abergel, RJ, "Active Actinium," *Nat Chem*., vol. 8, no. 11, pg. 1084 (November 2016) ("Abergel 2016")

Exhibit No.	Description
2115	Pallares RM and Abergel RJ, Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand? *Front. Med.* 2022; 9:1020188 ("Abergel 2022")
2116	Burnett, AK, et al, A Comparison of Low Dose Cytarabine and Hydroxyurea With or Without All trans Retinoic Acid for Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome in Patients Not Considered Fit for Intensive Treatment, *Cancer* 2007; 109:1114-24 ("Burnett")
2117	Winter, JN, et al., Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. *Cancer* 1985; 56(3):443-9 ("Winter")
2118	Tilly, H, et al., Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients, *Cancer* 1985; 55(8):1633-6 ("Tilly")
2119	Cheson, BD, et al., A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes, *J Clin Oncol* 1986; 4(12):1857-64 ("Cheson")
2120	Lin M, et al., Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives, *Cancer Biother Radiopharm* 2021 Apr;36(3):237-251 ("Lin")
2121	Morton, JJ, et al. Humanized mouse xenograft models: narrowing the tumor-microenvironment gap, *Cancer Res.* 2016; 76(21): 6153–6158 ("Morton")
2122	Zacherl, MT, et al., First Clinical Results for PSMA-Targeted a-Therapy Using ^{225}Ac-PSMA-I&T in Advanced-mCRPC Patients, J. *Nucl. Med.* 2021; 62:669-674 ("Zacherl")

Exhibit No.	Description
2123	Fanti, S, et al. Highlights of the 30th Annual Congress of the EANM, Vienna 2017: "Yes we can – make nuclear medicine great again," *Eur. J. Nuc. Med. Mol. Im*. 2018; 45:1781–1794 ("Fanti")
2124	https://www.eanm.org/congresses-events/awards-grants/winners/
2125	Nonnekens, J., et al., ^{213}Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-StrandBreaks in Prostate Cancer Xenografts, *Canc. Bioth. Rad*. 2017, 32 (2), 67-73 ("Nonnekens")
2126	Alam, MR, et al., A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer, *Cureus* 2022; 14(9): e29369 ("Alam")
2127	Feuerecker, B., et al., Clinical Translation of Targeted a-Therapy: An Evolution or a Revolution? *J Nucl Med* 2023; 64:685–692 ("Feuerecker")
2128	Lepareur, N. An overview of current phase 3 radiopharmaceutical therapy clinical trials *Front. Med.* 2025 12:1549676. ("Lepareur")
2129	Jalloul, W., *et al*. Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management *Pharmaceuticals* **2025**, 18, 1215 ("Jalloul")
2130	Munekane, M, et. al., Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics, *Anal. Sci.* **2024** 40:803-826. ("Munekane")
2131	PubMed results: Ex. 1045 Kratochwil 2016 last visited October 21, 2025
2132	PubMed results: Ex. 1028: Weineisen 2015 last visited October 21, 2025
2133	Google Scholar results: Ex. 1028: Weineisen 2015 last visited October 21, 2025

Exhibit No.	Description
2134	Zalutsky, MR and Pruszynski, M, Astatine-211: production and availability. *Current radiopharmaceuticals* 2011;4(3):177-185.
2135	Nordstrom, M. *et al*, Identification of plasma protein profiles associated with risk groups of prostate cancer patients, *Proteomics Clin. Appl.* 2014 December; 8(0): 951-962 ("Nordstrom")
2136	Afshar-Oromieh, A., *et al*, The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer, *J. Nucl. Med.* 2016; 57:79S-89S, DOI: 10.2967/jnumed.115.170720 ("Afshar-Oromieh")
2137	Berney, DM *et al*, Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome, *British Journal of Cancer* (2016) 114, 1078-1083, doi: 10.1038/bjc.2016.86 ("Berney)
2138	Declaration of Dr. Michael Gorin, M.D.
2139	Deposition of Michael Rod Zalutsky, Ph.D. taken July 30, 2026
2140	Rowe, SP, *et al*, Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer, . *Nucl. Med.* 2016; 57:90S-96S, DOI: 10.2967/jnumed.115.170175 ("Rowe")
2141	National Center for Biotechnology Information. PubChem Compound Summary for CID 156596528, Zadavotide guraxetan. https://pubchem.ncbi.nlm.nih.gov/compound/156596528#section=2D-Structure. Accessed Aug. 15, 2026.
2142	National Center for Biotechnology Information. PubChem Compound Summary for CID 158782, https://pubchem.ncbi.nlm.nih.gov/compound/158782. Accessed Aug. 15, 2026.
2143	Boy, C. *et al*, ^{68}Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax, *Eur. J. Nucl. Med. Mol. Imaging* (2011) 38:1224-1236, DOI 10.1007/s00259-011-1760-x ("Boy")

Exhibit No.	Description
2144	Obata, H. *et al*, DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy, *Pharmaceutics*, 2023, 15, 1926 https://doi.org/10.3390/pharmaceutics15071926 ("Zalutsky 2023")
2145	Huynh, TT , *et al*, Enhancing the Therapeutic Index of [^{211}At]YF2 with Iodo Pseudo Carrier: A Simple Strategy for Reducing Accumulation in Kidneys, Salivary and Lacrimal glands, *Nucl Med Biol*. 2025; 146-147: 109028 doi:10.1016/j.nucmedbio.2025.109028
2146	Vaidyanathan, G. and Zalutsky, M.R., Applications of ^{211}At and ^{223}Ra in Targeted Alpha-Particle Radiotherapy, *Curr Radiopharm*, 2011 October; 4(4): 283-294
2147	Mease, RC, *et al*, An Improved ^{211}At-Labeled Agent for PSMA-Targeted α-Therapy, *J Nucl Med* 2022; 63-259-267, DOI: 10.2967/jnumed.121.262098 ("Zalutsky 2022")
2148	Zalutsky, M.R. and Pruszynski, M., Astatine-211: Production and Availability, *Curr Radiopharm.* 2011 July; 4(3): 177-185 ("Zalutsky 2011")
2149	Maguire, W.F., *et al*, Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with ^{225}Ac for α-Particle Radioimmunotherapy of Cancer, *J Nucl Med*, 2014; 55(9):1492-1498, DOI: 10.2967/jnumed.114.138347
2150	Declaration of Mirjam Weis
2151	Declaration of Prof. Federick A. Verburg, MD, Ph.D.
2152	Declaration of Prof. Dr. Felix Mottaghy
2153	Vaidyanathan, G., *et al*, Synthesis and Preliminary Evaluation of ^{211}At-labeled Inhibitors of Prostate-Specific Membrane Antigen for Targeted Alpha Particle Therapy of Prostate Cancer, *Nucl Med Biol.* 2021; 94-95: 67-80. doi:10.1016/j.nucmedbio.2021.01.002.
2154	Supplemental Declaration of Clemens Kratochwil, M.D.

Exhibit No.	Description
2155	Kratochwil, C., et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience, *Eur. J. Nucl. Med. Mol. Imaging*, 2014; 41:2106–2119
2156	Michael Gorin CV
2157	Michael Gorin List of Materials Considered
2158	Kiess, et al. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl) Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle, *J Nucl Med* 2016; 57:1569–1575
2159	Vallabhajosula et al., Prediction of Myelotoxicity Based on Bone Marrow Radiation-Absorbed Dose: Radioimmunotherapy Studies Using 90Y- and 177Lu-Labeled J591 Antibodies Specific for Prostate-Specific Membrane Antigen, *J. Nucl. Med*., Vol, 46, No. 5, pgs. 850-858 (2005)
2160	Cloutier, et al., MIRD Pamphlet No. 21, Dose Estimate Report No. 2, "Summary of Current Radiation Dose Estimates to Humans from 66Ga-, 67Ga-, 68Ga-, and 72Ga-citrate," J. Nucl. Med., vol. 14, no. 10, pgs. 755-756 (1973).
2161	Jaggi, SJ, et al. Efforts to Control the Errant Products of a Targeted In vivo Generator, *Cancer Res.* 2005; 65: (11)
2162	Forrer, F, et al., Treatment with 177Lu-DOTATOC of Patients with Relapse of Neuroendocrine Tumors After treatment with 90Y-DOTATOC, *J Nucl Med.* 2005; 46:1310–1316
2163	Dorso, L, et al., Long-Term Toxicity of 213Bi-Labelled BSA in Mice, PLOS ONE 2016; 11(3), e0151330
2164	Common Terminology Criteria for Adverse Events (CTCAE), V. 5.0, November 27, 2017, U.S. Dept. Health & Human Services.

Exhibit No.	Description
2165	Sathekge, M. , et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study Lanc. Onc., 25 (2), 2024, p. 175-183.
2166	Ex. 1027: Weineisen 2014 Pubmed
2167	Ex. 1027: Weineisen 2014 Google
2168	Ex. 1006: Chatalic Google
2169	Ex. 1015: Miederer Pubmed
2170	Ex. 1015: Miederer Google
2171	Ex. 1011: Jurcic Google
2172	Ex. 1031: Kratochwil Google
2173	Afshar-Oromieh et al., The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions, *J. Nucl. Med.*, vol. 56, no. 11, 1697-1705 (2015).
2174	Schwartz et al., Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody, *Phys. Med. Biol.* Vol. 56, no. 3, pgs. 721-733 (2011).
2175	Tagawa ST, et al., Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer, *Cancer* 2010, 116(4 Suppl):1075-83.
2176	Tagawa ST, et al., Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer, *Front Oncol* 2013, 26:3:214

Exhibit No.	Description
2177	Tagawa ST, et al., Prostate-Specific Membrane Antigen- Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591, *J Clin Oncol* 2023, 3:JCO2300573
2178	Zalutsky et al., Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6, *J. Nucl. Med.* Vol. 49, no. 1, pgs. 30-38 (2008)
2179	Abbas et al., Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl- DOTA-trastuzumab, *EJNMMI Res.* Vol. 1, no. 1, pg.18 (2011)
2180	Parker et al., Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, *N. Engl. J. Med.* Vol 369, no. 3, pgs. 213-223
2181	Meredith et al., Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab, *J. Nucl. Med.*, vol. 55, no. 10, pgs. 1636-1642 (2014)
2182	Cordier et al., Targeted alpha- radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA- [Thi8,Met(O2)11]-substance P: a pilot trial, *Eur. J. Nucl. Med. Mol. Imaging*, vol. 37, no. 7, pgs. 1335-1344 (2010)
2183	Müller et al., A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of- concept study with a new receptor-targeted folate derivative, *J. Nucl. Med.*, vol. 53, no. 12, pgs. 1951-1959 (2012).
2184	Pimm et al, Blood and tissue kinetics of radiolabelled anti-CEA monoclonal antibody and F(ab)2 and Fab fragments in nude mice with human tumour xenografts: implications for tumour imaging and radioimmunotherapy, *Nucl. Med. Commun.*, vol. 10, no. 8, pgs. 585-593 (1989)

Exhibit No.	Description
2185	Sathekge, M., et al., 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study, *Eur J Nucl Med Mol Imaging* 2019, 46:129–138
2186	Alan-Selcuk, N. *et al.*, Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer, *J Nucl Med* 2023 Oct;64(10):1574-1580
2187	Kauffman, N. *et al.*, Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics, *Pharmaceutics* 2023 Apr; 15(4):1138
2188	Okamoto, S. *et al.*, Clinical Perspectives of Theranostics, *Molecules* 2021 Apr; 26(8):2232
2189	Oyen, W.J. and de Bono, J.S., Targeted α-Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?, *J Nucl Med* 2016 Dec; 57(12): 1838-1839
2190	Corrected Exhibit 2157-List of Materials Considered by Dr. Michael A. Gorin, M.D.